Patent intelligence · WO
WO 2021182981
OPICAPONE MICRONISÉE
OPICAPONE MICRONISÉE
Patent details — WO 2021182981
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Sep 16, 2021
- Expiration
- Sep 11, 2041
- Applicant
- BIAL PORTELA & Cª S A [PT]
- CPC classes
- A61K 9/ 16 A I, A61K 9/ 20 A I, A61K 31/ 4439 A I, A61K/314439
Quick answer
WO 2021182981 (OPICAPONE MICRONISÉE) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Sep 16, 2021. Expires Sep 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 16 A I, A61K 9/ 20 A I, A61K 31/ 4439 A I, A61K/314439, A61K/916, A61K/91688
More from BIAL PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2021182981?
WO 2021182981 (OPICAPONE MICRONISÉE) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Sep 16, 2021. Expires Sep 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2021182981?
BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does WO 2021182981 expire?
Our index shows an expiration date of Sep 11, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.